Longevity & AgingNew Dual Agonist Survodutide Cuts Weight 13% But Side Effects Drive One in Five to Quit
Survodutide, a dual glucagon and GLP-1 receptor agonist, achieved up to 13% body weight loss over 76 weeks in people with obesity in a phase III trial. It also reduced liver fat in patients with metabolic liver disease (MASLD). However, gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation — affected up to 90% of treated patients, and roughly one in five stopped treatment because of them. The drug did not raise blood sugar levels in non-diabetic participants. Results were presented at the American Diabetes Association Scientific Sessions and published simultaneously in the New England Journal of Medicine. Researchers acknowledged the rigid trial design may have inflated dropout rates, suggesting real-world flexibility in dosing could improve tolerability.
